Literature DB >> 22810135

Management of malignant gliomas and primary CNS lymphoma: standard of care and future directions.

Myrna R Rosenfeld1, Amy A Pruitt.   

Abstract

PURPOSE OF REVIEW: This article review the current standard of care of astrocytic gliomas and primary CNS lymphoma and discusses promising new therapeutic targets. RECENT
FINDINGS: Standard treatment modalities for primary malignant brain tumors include resection, radiation, local or systemic chemotherapy, and, most recently, antiangiogenic agents. However, these tumors often have a rapid course, and patients usually die within a few years of diagnosis. Improved surgical techniques and radiation and chemotherapy can prolong survival while maintaining quality of life, but these therapies remain inadequate.
SUMMARY: The care of patients with malignant brain tumors is challenging. A better understanding of the pathogenesis of primary malignant brain tumors and the elucidation of aberrant molecular pathways are leading to novel treatment strategies and the ability to identify patients who may benefit from specific treatments.

Entities:  

Mesh:

Year:  2012        PMID: 22810135     DOI: 10.1212/01.CON.0000413666.88539.0b

Source DB:  PubMed          Journal:  Continuum (Minneap Minn)        ISSN: 1080-2371


  7 in total

Review 1.  Current concepts in diagnosing and managing primary vitreoretinal (intraocular) lymphoma.

Authors:  Chi-Chao Chan; H Nida Sen
Journal:  Discov Med       Date:  2013-02       Impact factor: 2.970

Review 2.  Diagnostic vitrectomy for primary intraocular lymphoma: when, why, how?

Authors:  Cindy S Hwang; Steven Yeh; Chris S Bergstrom
Journal:  Int Ophthalmol Clin       Date:  2014

Review 3.  Hemiplegia and headache: a review of hemiplegia in headache disorders.

Authors:  J Ivan Lopez; Ashley Holdridge; John F Rothrock
Journal:  Curr Pain Headache Rep       Date:  2015

4.  Diagnostic delay and prognosis in primary central nervous system lymphoma compared with glioblastoma multiforme.

Authors:  R Cerqua; S Balestrini; C Perozzi; V Cameriere; S Renzi; G Lagalla; G Mancini; M Montanari; P Leoni; M Scerrati; M Iacoangeli; M Silvestrini; S Luzzi; L Provinciali
Journal:  Neurol Sci       Date:  2015-08-02       Impact factor: 3.307

Review 5.  Primary vitreoretinal lymphoma: prevalence, impact, and management challenges.

Authors:  Ramesh Venkatesh; Bharathi Bavaharan; Padmamalini Mahendradas; Naresh Kumar Yadav
Journal:  Clin Ophthalmol       Date:  2019-02-14

6.  Demethoxycurcumin analogue DMC-BH inhibits orthotopic growth of glioma stem cells by targeting JNK/ERK signaling.

Authors:  Lei Shi; Guan Sun; Haifeng Zhu
Journal:  Aging (Albany NY)       Date:  2020-07-24       Impact factor: 5.682

Review 7.  Recent progress in the diagnosis and treatment of primary vitreoretinal lymphoma.

Authors:  Min Zhou; Gezhi Xu
Journal:  Taiwan J Ophthalmol       Date:  2016-06-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.